Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGAL | P20701 | 3/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.82 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.82 |
| ▸ | IGF2BP1 | Q9NZI8 | 2/20 | 0.82 |
| ▸ | NPC1 | O15118 | 2/20 | 0.82 |
| ▸ | RAB9A | P51151 | 2/20 | 0.82 |
| ▸ | LMNA | P02545 | 1/20 | 0.82 |
| ▸ | MAPT | P10636 | 1/20 | 0.82 |
| ▸ | STAT3 | P40763 | 1/20 | 0.82 |
| ▸ | HTT | P42858 | 1/20 | 0.82 |
| ▸ | ATM | Q13315 | 1/20 | 0.82 |
| ▸ | PAX8 | Q06710 | 2/20 | 0.68 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 2/20 | 0.45 |
| ▸ | TYR | P14679 | 1/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cucurbitacin D SCHEMBL8166627 | 1.00 | ITGAL (1.00) | ITGALSMN1; SMN2HIF1AIGF2BP1NPC1 | |
| Cucurbitacin D SCHEMBL230654 | 1.00 | ITGAL (1.00) | ITGALSMN1; SMN2HIF1AIGF2BP1NPC1 | |
| SCHEMBL10307568 | 0.95 | ITGAL (0.90) | ITGALSMN1; SMN2HIF1AIGF2BP1NPC1 | |
| SCHEMBL21650384 | 0.92 | ITGAL (0.86) | ITGALSMN1; SMN2HIF1AIGF2BP1NPC1 | |
| Amarin SCHEMBL17531553 | 0.90 | ITGAL (1.00) | ITGALSMN1; SMN2HIF1AIGF2BP1NPC1 | |
| Amarin SCHEMBL19186443 | 0.90 | ITGAL (1.00) | ITGALSMN1; SMN2HIF1AIGF2BP1NPC1 | |
| Cucurbitacin B SCHEMBL29602393 | 0.90 | ITGAL (1.00) | ITGALSMN1; SMN2HIF1AIGF2BP1NPC1 | |
| Amarin SCHEMBL22433345 | 0.90 | ITGAL (1.00) | ITGALSMN1; SMN2HIF1AIGF2BP1NPC1 | |
| Amarin SCHEMBL18177462 | 0.90 | ITGAL (1.00) | ITGALSMN1; SMN2HIF1AIGF2BP1NPC1 | |
| Amarin SCHEMBL13668120 | 0.90 | ITGAL (1.00) | ITGALSMN1; SMN2HIF1AIGF2BP1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3763419-A1 | CHEMOSENSORY RECEPTOR LIGAND-BASED THERAPIES | Anji Pharma (US) LLC (US) | 2021-01-13 | — | — | EP | disclosed |
| US-10610500-B2 | Chemosensory receptor ligand-based therapies | ANJI PHARMA (US) LLC (US) | 2020-04-07 | — | — | US | disclosed |
| US-20190038576-A1 | Chemosensory Receptor Ligand-Based Therapies | ANJI PHARMACEUTICALS INC. | 2019-02-07 | — | — | US | disclosed |
| US-9962344-B2 | Chemosensory receptor ligand-based therapies | ELCELYX THERAPEUTICS, INC. (US) | 2018-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10610500-B2 | Chemosensory receptor ligand-based therapies | TAS1R2, TAS2R1, GPR119 | ITGAL 2328/4885SMN1; SMN2 2730/4885HIF1A 738/4885 |
| US-20190038576-A1 | Chemosensory Receptor Ligand-Based Therapies | TAS1R2, TAS2R1, GPR119 | ITGAL 2328/4885SMN1; SMN2 2730/4885HIF1A 738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.